Charles Schwab Investment Management Inc. Boosts Stake in Cerus Co. (NASDAQ:CERS)

Charles Schwab Investment Management Inc. lifted its holdings in Cerus Co. (NASDAQ:CERS) by 0.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,754,540 shares of the biotechnology company’s stock after purchasing an additional 8,707 shares during the period. Charles Schwab Investment Management Inc. owned about 0.94% of Cerus worth $3,053,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of CERS. Secure Asset Management LLC acquired a new stake in Cerus in the second quarter valued at approximately $27,000. Creative Planning grew its stake in Cerus by 51.3% in the 3rd quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 8,411 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in Cerus in the 2nd quarter valued at $45,000. Intech Investment Management LLC purchased a new stake in Cerus in the 3rd quarter worth $71,000. Finally, Algert Global LLC acquired a new position in Cerus during the second quarter worth $97,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Stock Performance

Shares of NASDAQ:CERS opened at $1.71 on Friday. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. Cerus Co. has a 1 year low of $1.38 and a 1 year high of $2.59. The firm has a market capitalization of $317.57 million, a PE ratio of -15.55 and a beta of 1.24. The business’s 50 day moving average price is $1.75 and its 200-day moving average price is $1.91.

Analyst Ratings Changes

Separately, Stifel Nicolaus dropped their target price on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.